#JustIn | #Biocon Arm gets tentative US FDA nod for Rifaximin tablets in partnership with #CarnegiePharma

🚩Alert: #Rifaximin tablets are antibiotics used to reduce the risk of hepatic encephalopathy recurrence

#Biocon arm receives tentative US FDA approval for tablets used to treat #stomach ailments

#JustIn | #Biocon Biologics Arm gets #Canada regulator’s nod for Yesintek Biosimilar

🚩Alert: #Yesintek Biosimilar is used for the treatment of moderate to severe plaque psoriasis

#JustIn | #Biocon Says: Constituting a committee to evaluate options for restructuring including the merger of BBL & BL

▶️Strategic options for restructuring include merger of Biocon Biologics with Co

#JustIn | #Biocon gets final US FDA nod for its ANDA for #Tofacitinib extended-release tablets

Citi downgrades #Biocon to 'sell' from 'buy', target at ₹360/sh

Adverse biosimilar pricing & change in FDA guidelines may weigh on margin & valuations: Citi

#JustIn | #Biocon announces settlement agreement with #Amgen

▶️Amgen settlement agmt clears path for commercialisation of #Denosumab biosimilars in #Europe & RoW

🚩Amgen agmt allows co to commercialise both Denosumab biosimilars in Europe w.e.f Dec 2

#JustIn | #Biocon to fully integrate #BioconBiologics as its wholly-owned subsidiary, subject to approvals

▶️Co to acquire remaining stake in Biocon Biologics via share swap, valuing it at $5.5 bn

▶️Biocon to acquire Mylan’s (#Viatris) remaining stake for $815 m, including a share swap at Rs 405.78/sh

▶️Integration expected to be completed by March 31, 2026

▶️Board approves swap ratios, & raising up to Rs 4,500 cr ($500 m) via QIP, subject to shareholder approval

#JustIn | #Biocon;

S&P Global places co on +ve CreditWatch on account of accelerated debt reduction

#JustIn | #Biocon receives Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) from US FDA for Co’s facility in New Jersey

Alert: The inspection was conducted from October 6-10, 2025

#JustIn | #Biocon signs out-licensing agreement with #Ajanta to market Semaglutide in 26 countries

#JustIn | #Biocon board approves QIP, Floor Price at ₹387.74/Sh

#JustIn | #Biocon QIP launched;

▶️Issue Size At ₹4,150 Cr

▶️Indicative Price At ₹368.35/Sh, At 5% Discount To CMP

#JustIn | #Biocon: Fitch Ratings upgrades Arm #BioconBiologics outlook from ‘Stable’ to ‘Positive’

#JustIn | #Biocon announces #US commercial launch of Bosaya & Aukelso, Denosumab biosimilars

Alert: Bosaya is used to treat osteoporosis, while Aukelso is used for cancer-related bone health issues

#JustIn | #Biocon receives Health Canada approval for Denosumab biosimilars

Alert: #Denosumab aids bone health by increasing bone mass & treating osteoporosis

#JustIn | #Biocon Pharma receives Health Canada approval for micafungin for injection Alert: #Micafungin is used for treatment of patients with candidemia

#JustIN | #Biocon Publishes Clinical Data Supporting Effectiveness Of Yesafili, Biosimilar To Eylea (Aflibercept)

#BlockDeal | Sources Say Block Deal Launched In #Biocon

💊Active Pine Likely To Sell Up To 1.66 Cr Shares (1% Eq) In Co Via Block Deal

#JustIN | #Biocon: License Agmt With Janssen Sciences For Commercialisation Of Yesintek In Addl Global Mkts

🚩Alert: #Yesintek Is Used In Treatment Of Crohn’s Disease, Ulcerative Colitis, Plaque Psoriasis